Search

Your search keyword '"Visser, J V"' showing total 5 results
Start Over Author "Visser, J V"
5 results on '"Visser, J V"'

1. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program

Author

van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, van den Bergh, J P W, van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, and van den Bergh, J P W

Abstract

This study evaluated the 2-year persistence with teriparatide in the Netherlands. Analyses showed that the risk of non-persistence was 28% lower in patients who were followed according to an additional educational and motivational support program.INTRODUCTION: Until recently, teriparatide (TPTD) was a third-line treatment option for severe osteoporosis in the Netherlands, which could only be prescribed by medical specialists based on a specific medical statement. We aimed to determine whether an educational and motivational support program (EMSP) increased 2-year treatment persistence with TPTD in patients with severe osteoporosis.METHODS: We evaluated persistence in 1573 Dutch patients treated with TPTD from January 2013 until January 2018. From January 2013 onwards, all patients received a basic support program (BSP) consisting of an educational home visit to initiate TPTD treatment and phone calls (at 1, 2.5 and 8 weeks). Since May 2015, all patients received the EMSP consisting of the BSP extended with evaluation of medication adherence during phone calls, an additional phone call (at 12 months), and motivational letters at 9 and 14 months.RESULTS: The EMSP showed a statistically significantly higher 2-year persistence (78%) with TPTD as compared with the BSP (72%). Reasons for treatment discontinuation were comparable between groups, except for the proportion of patients who had stopped TPTD administration due to side effects, which was significantly lower in the EMSP group (8% vs. 15% in BSP, p < 0.001). Overall, the risk of non-persistence was 28% lower in the EMSP compared with the BSP group (HR: 0.72; 95% CI: 0.55-0.93).CONCLUSION: The introduction of the EMSP has demonstrated to improve the persistence with TPTD, resulting in 78% of the patients being persistent with TPTD during the 2-year treatment period.

Published
2019

2. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, van den Bergh, J P W, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, and van den Bergh, J P W

Published
2019

3. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program

Author

MS Geriatrie, Circulatory Health, van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, van den Bergh, J P W, MS Geriatrie, Circulatory Health, van Maren, M A, Wyers, C E, Driessen, J H M, Visser, J V, de Vries, F, van de Wijdeven, K, Gevers, S, Lems, W F, Emmelot-Vonk, M H, and van den Bergh, J P W

Published
2019

4. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.

Author

van Maren MA, Wyers CE, Driessen JHM, Visser JV, de Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, and van den Bergh JPW

Subjects
Age Factors, Aged, Aged, 80 and over, Bone Density Conservation Agents therapeutic use, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Medication Adherence psychology, Middle Aged, Motivation, Netherlands, Osteoporosis, Postmenopausal drug therapy, Retrospective Studies, Risk Assessment methods, Sex Factors, Telephone, Teriparatide therapeutic use, Bone Density Conservation Agents administration & dosage, Medication Adherence statistics & numerical data, Osteoporosis drug therapy, Patient Education as Topic methods, Teriparatide administration & dosage
Abstract

This study evaluated the 2-year persistence with teriparatide in the Netherlands. Analyses showed that the risk of non-persistence was 28% lower in patients who were followed according to an additional educational and motivational support program., Introduction: Until recently, teriparatide (TPTD) was a third-line treatment option for severe osteoporosis in the Netherlands, which could only be prescribed by medical specialists based on a specific medical statement. We aimed to determine whether an educational and motivational support program (EMSP) increased 2-year treatment persistence with TPTD in patients with severe osteoporosis., Methods: We evaluated persistence in 1573 Dutch patients treated with TPTD from January 2013 until January 2018. From January 2013 onwards, all patients received a basic support program (BSP) consisting of an educational home visit to initiate TPTD treatment and phone calls (at 1, 2.5 and 8 weeks). Since May 2015, all patients received the EMSP consisting of the BSP extended with evaluation of medication adherence during phone calls, an additional phone call (at 12 months), and motivational letters at 9 and 14 months., Results: The EMSP showed a statistically significantly higher 2-year persistence (78%) with TPTD as compared with the BSP (72%). Reasons for treatment discontinuation were comparable between groups, except for the proportion of patients who had stopped TPTD administration due to side effects, which was significantly lower in the EMSP group (8% vs. 15% in BSP, p < 0.001). Overall, the risk of non-persistence was 28% lower in the EMSP compared with the BSP group (HR: 0.72; 95% CI: 0.55-0.93)., Conclusion: The introduction of the EMSP has demonstrated to improve the persistence with TPTD, resulting in 78% of the patients being persistent with TPTD during the 2-year treatment period.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results